Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its investigational drug candidate GR1802, an interleukin-4 receptor α (IL-4Rα) monoclonal antibody (mAb). The drug is intended to be assessed as a treatment for anaphylactic rhinitis.
GR1802 selectively binds to IL-4Rα, effectively blocking both the IL-4 and IL-13 signaling pathways, which play a critical role in type 2 immunity. By regulating this immune response, GR1802 aims to reduce eosinophil and IgE levels. The drug is under development for the treatment of autoimmune diseases that exhibit high expression of IL-4 and IL-13, including type 2 immune-mediated asthma, atopic dermatitis, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis, among others.- Flcube.com
